2018
Ataxia Telangiectasia Mutated Protein Loss and Benefit From Oxaliplatin-based Chemotherapy in Colorectal Cancer
Sundar R, Miranda S, Rodrigues D, Chénard-Poirier M, Dolling D, Clarke M, Figueiredo I, Bertan C, Yuan W, Ferreira A, Chistova R, Boysen G, Perez D, Tunariu N, Mateo J, Wotherspoon A, Chau I, Cunningham D, Valeri N, Carreira S, de Bono J. Ataxia Telangiectasia Mutated Protein Loss and Benefit From Oxaliplatin-based Chemotherapy in Colorectal Cancer. Clinical Colorectal Cancer 2018, 17: 280-284. PMID: 30042009, DOI: 10.1016/j.clcc.2018.05.011.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsAtaxia Telangiectasia Mutated ProteinsBiomarkers, TumorColorectal NeoplasmsDNA RepairFemaleFollow-Up StudiesGene Expression Regulation, NeoplasticHumansLiver NeoplasmsMaleMiddle AgedOxaliplatinPrognosisRetrospective StudiesSurvival RateYoung AdultConceptsATM lossColorectal cancerAssociated with superior overall survivalDNA repair targeting agentsMetastatic colorectal cancer patientsAtaxia telangiectasiaIrinotecan-based therapySuperior overall survivalOxaliplatin-based therapyOxaliplatin-based chemotherapyTreatment of colorectal cancerATM protein expressionClinical outcome dataNuclear staining intensityColorectal cancer patientsDrug Development UnitColorectal cancer samplesOverall survivalMutation statusH-scoreTargeted agentsClinical outcomesDNA repair signalingTumor samplesCancer patients
2017
Abstract 3807: ATM protein loss and clinical outcomes with platinum chemotherapy in patients with advanced solid tumors
Sundar R, Miranda S, Carreira S, Chénard-Poirier M, Rodrigues D, Figueiredo I, Bertan C, Yuan W, Perez D, Ferreira A, Tunariu N, Mateo J, Bono J. Abstract 3807: ATM protein loss and clinical outcomes with platinum chemotherapy in patients with advanced solid tumors. Cancer Research 2017, 77: 3807-3807. DOI: 10.1158/1538-7445.am2017-3807.Peer-Reviewed Original ResearchATM protein lossAdvanced solid tumorsPlatinum chemotherapyPlatinum therapyATM lossClinical outcomesMetastatic sitesATM mutationsIHC lossSolid tumorsNext generation sequencingAmerican Association for Cancer Research annual meetingsSensitivity to platinum therapySomatic ATM mutationsAdvanced solid cancersSites of patientsNuclear staining intensityRabbit monoclonal antibodyLoss of ATM expressionProtein lossColorectal cancer cohortDNA damage repair signalingTP53 mutationsArchival tumorsH-score